New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.59 0.53 +1.15%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Revenue to profit Fiscal 2025, year to Dec 31, 2025

Of every $100 of revenue, $10.57 was left as profit. Gross margin has risen two years running, from 69.3% to 72.1%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue52.9100.0%
Cost of revenue−14.8−27.9%
Gross profit38.172.1%
Research & development−8.9−16.8%
Selling, general & admin−10.8−20.4%
Other operating costs−8.6−16.3%
Operating income9.818.6%
Other income, net−2.8−5.4%
Income tax−1.2−2.2%
Other items−0.2−0.4%
Net income5.610.6%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$38.4B$40.9B$42.1B$42.1B$42.7B$46.3B$47.8B$50.3B$47.9B$52.9B
Operating income$7.6B$7.1B$6.2B$7.3B$16.4B$9.8B$10.7B$9.6B$8.2B$9.8B
Net income$5.2B$9.5B$5.1B$3.1B$14.1B$7.4B$8.8B$5.8B$5.9B$5.6B
Net margin (right axis)13.6%23.3%12.1%7.5%33.0%15.9%18.4%11.6%12.4%10.6%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
52,854.48 47,921.88 50,266.34 47,821.85 46,347.94 42,686.61 42,146.72 42,134.54 40,921.38 38,407.87
Revenue Growth
10.29% (4.66%) 5.11% 3.18% 8.58% 1.28% 0.03% 2.96% 6.54% (0.78%)
Gross Profit
38,090.84 33,632.75 34,858.72 33,392.80 31,849.05 28,799.67 28,733.60 28,629.80 27,797.47 26,565.04
Operating Income
9,830.73 8,219.63 9,593.50 10,720.38 9,845.76 16,388.58 7,269.91 6,232.14 7,070.03 7,592.38
EBT
6,986.40 7,247.91 7,741.69 10,980.62 9,225.81 15,768.31 3,160.64 5,202.31 6,250.56 6,283.28
Income after Tax
5,806.35 5,945.06 6,007.85 8,867.10 7,382.54 13,697.32 3,004.96 4,634.24 4,304.18 4,815.92
Net Income Common
8,839.63 6,016.48 5,844.42 8,819.69 7,362.43 14,066.28 3,142.72 5,085.39 9,532.95 5,210.98
EPS (Diluted)
3.62 2.48 2.33 3.51 2.94 5.61 1.24 2.04 1.75 2.03
Shares (Diluted, Weighted)
2,451.20 2,512.20 2,512.80 2,513.80 2,515.80 2,520.20 2,514.20 2,510.40 2,533.60 2,592.00
Gross Margin
72.07% 70.18% 69.35% 69.83% 68.72% 67.47% 68.18% 67.95% 67.93% 69.17%
EBIT Margin
18.60% 17.15% 19.09% 22.42% 21.24% 38.39% 17.25% 14.79% 17.28% 19.77%
Net Profit Margin
16.72% 12.55% 11.63% 18.44% 15.89% 32.95% 7.46% 12.07% 23.30% 13.57%
Free Cash Flow Margin
17.25% 16.59% 17.76% 21.62% 23.48% 16.73% 19.01% 16.07% 16.46% 17.18%
EBITDA
16,254.82 12,100.04 14,779.89 14,323.69 13,810.33 20,596.81 15,616.15 11,285.64 11,236.31 11,245.27
EBIT
9,830.73 8,219.63 9,593.50 10,720.38 9,845.76 16,388.58 7,269.91 6,232.14 7,070.03 7,592.38

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026